Karyopharm Therapeutics reported $37.1M in Gross Profit on Sales for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US 1.74M 341K
Abbott ABT:US $ 6505M 1225M
Amgen AMGN:US $ 5097M 208M
AstraZeneca AZN:LN 6.04B 15M
Astrazeneca AZN:US 6.04B 15M
Biocryst Pharmaceuticals BCRX:US $ 40.38M 9.24M
Bristol Myers Squibb BMY:US $ 9333M 81M
Eli Lilly And LLY:US $ 5342M 555.1M
Epizyme EPZM:US $ 3.2M 7.32M
GlaxoSmithKline GSK:LN 6.26B 682M
Johnson & Johnson JNJ:US $ 16088M 343M
Karyopharm Therapeutics KPTI:US $ 37.1M 15.64M
MacroGenics MGNX:US 14M 16.74M
Merk MRK:US $ 10098M 1738M
Nektar Therapeutics NKTR:US $ 19.61M 1.05M
Novartis NOVN:VX 9.52B 21M
Novartis NVS:US $ 9519M 21M
Pfizer PFE:US $ 14163M 2178M
Regeneron Pharmaceuticals REGN:US $ 2999.6M 1445.2M
Takeda 4502:JP Y 569023M 139316M
Ultragenyx Pharmaceutical RARE:US $ 77.47M 6.37M
YTE INCY:US $ 778.52M 105.44M